Swiss software company SOPHiA GENETICS and Paraguay-based Laboratorio Curie have expanded their partnership under which Laboratorio Curie will deploy the SOPHiA DDM Platform.
SOPHiA DDM Platform is a cloud-native platform that can analyse data and generate insights from complex multimodal data sets and different diagnostic modalities.
Under the partnership, Laboratorio Curie will use the SOPHiA DDM Platform technology to deploy a new test for BRCA gene mutation identification.
The results of this test are intended to allow the software company to assist the country’s expanding use of precision medicine for hereditary malignancies, the Swiss firm said.
With the SOPHiA DDM Platform, Laboratorio Curie will use next-generation sequencing (NGS) to check for BRCA gene mutations, which have been associated with an elevated risk of numerous cancers including breast and ovarian cancer.
Laboratorio Curie lab director Dra. Filartiga said: “At Laboratorio Curie our mission is research, even behind the most clinical analyses. It is this passion that guides us to advance science and work every day to discover ways to make a difference in people’s lives.”
“Thanks to the commitment, dedication, and effort of our team, today we are considered an outstanding benchmark in Paraguay.
“Being pioneers in precision medicine in cancer through genomics and hand in hand with SOPHiA GENETICS is a goal achieved with effort and perseverance, and we are proud to have the trust and respect of the medical community.”
The platform is said to be a technology-neutral tool that uses artificial intelligence (AI) to quickly assess and decipher unprocessed NGS data.
The SOPHiA DDM Platform will deliver precise and thoroughly examined results to Laboratorio Curie within two days, speeding up reporting and enabling data-driven decision-making for researchers, the Swiss company added.
SOPHiA GENETICS LAPAC MD Ricardo Mendonca Filho said: “By using the SOPHiA DDM Platform, Laboratorio Curie can ensure speed and accuracy of its NGS testing to best support investigations into BRCA-associated cancers.
“Additionally, the Lab will be able to amass a database of BRCA research that will map a more holistic view of how BRCA is impacting South Americans.”
